|
![]() |
|
|
Hydergine: profile and news
Complementary medicines in psychiatry Review of effectiveness and ... Feb 9, 2006 Alzheimer's drug could make everyone brainier Jan 26, 2006 Oil and gas shortages: Is there a refinery shortage too? Mar 29, 2005 Oil and gas shortages: Is there a refinery shortage too? Mar 29, 2005 Other information Indication For use as an adjunct therapy for patients with dementia Pharmacology Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia. Mechanism Of Action Ergoloid mesylates act centrally, decreasing vascular tone and slowing the heart rate, and acts peripherally to block alpha-receptors. One other possible mechanism is the effect of ergoloid mesylates on neuronal cell metabolism, resulting in improved oxygen uptake and cerebral metabolism, thereby normalizing depressed neurotransmitter levels. Drug Category Adrenergic alpha-Antagonists; Nootropic Agents; Vasodilator Agents; Sympatholytics; ATC:C04AE01 Brand Names/Synonyms Alkergot; CCK 179; Circanol; Co-Dergocrine Mesylate; Deapril-St; Dihydroergotoxin Mesilat; Dihydroergotoxin Mesylate; Dihydroergotoxin Methanesulfonate; Dihydroergotoxine Mesilate; Dihydroergotoxine Mesylate; Dihydroergotoxine Methanesulfonate; Dihydroergotoxine Methanesulphonate; ERGOLOID MESYLATES; Ergoloid Mesylate; Ergoloid Mesylates; Ergoloid Mesylates [Usan]; Gerimal; Hydergin; Hydergine; Hydergine Lc; Hydrogenated Ergot Alkaloids; Ischelium; Redergin; Trigot Dosage Forms CAPSULE; LIQUID; POWDER; POWDER FOR SOLUTION; SOLUTION; SYRUP; TABLET Absorption Rapidly but incompletely (~ 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism. Interactions Drug Interactions for Ergoloid Mesylate: No reported interactions. Chemical IUPAC Name Not Available Chemical Formula C33H45N5O5 Half Life 3.5 hours Drug Type Approved Drug # Accession No APRD00711 CAS Registry Number 8067-24-1 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |